Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Cadrenal Therapeutics

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
From Cadrenal Therapeutics
Via Business Wire
Tickers CVKD
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.